At the June 4, 2026 annual meeting, 10x Genomics stockholders elected three Class I directors, ratified Ernst & Young as auditor for FY2026, and approved advisory executive compensation.
Key takeaways
All three Class I director nominees (Saxonov, Hindson, Stuelpnagel) were elected with significant support, though John R. Stuelpnagel received the most votes against.
The appointment of Ernst & Young as independent auditor for FY2026 was ratified by a large majority, with only 0.2% votes against.